1. East Midlands Academic
Health Science Network –
Igniting Innovation
Dr Carl Edwards, Interim Industry Lead | East Midlands AHSN

2. East Midlands Academic Health Science Network
“Igniting Innovation”
Who are EMAHSN?
2
Dr Carl Edwards
Interim Industry Lead, EMAHSN

3. 3
• Introduced in “Innovation Health and Wealth” December 2011
• Comprehensive NHS, University and Industry collaboration
“Improving the identification, adoption and spread of innovative
healthcare”
• To serve population of 3-5 million
• Comprehensive coverage: 15 nationally, 5 year licence
• AHSN Guidance issued 20th June 2012
• Expression of Interest submission 20th July 2012
• Submission of Prospectus 1st October 2012
• Interview 3rd December 2012
• Feedback 20th May 2013
What is an Academic Health Science Network
[AHSN]?

4. 4
• Six key functions and levers:
• Promoting participation in research
• Translating research and learning into practice
• Collaborating on education and training
• Driving service improvement
• Ensuring information is at the core of AHSN work
• Wealth creation
• Must also address:
• NHS Outcomes Framework; NHS Midlands and East cluster
ambition[s]; “Sunset Review”; Six High Impact Innovations;
NICE guidance; specific suite of industry requirements
What are the AHSNs intended to do?

5. 5
Academic Health Science Networks (AHSNs)

6. Former mining
area with high
levels of
deprivation
and health
inequalities
Large,
dispersed
rural area
Large
migrant
workforce
High levels of
avoidable mortality
eg
smoking, alcohol, s
elf harm
Highest rate of hip
fractures in
England
Leicester
forecast to be
Britain’s first
‘majority
minority
ethnic’ city by
2012
Zero
deprivation
Top 10% life
expectancy
Corby has lowest
life expectancy in
the region (bottom
5%)
Significant migrant
workforce
EMAHSN Geography – where are we?
Multi-ethnic, diverse, metropolitan
populations in Leicester, Nottingham and
Derby
Stark difference in deprivation, and life
expectancy between the city and county
6

7. EMAHSN vision and values - what do we stand for?
7

8. EMAHSN operational delivery How will we work?
8

9. EMAHSN and the New NHS Architecture – February 2013
9

10. 10
East Midlands Academic Health Science Network
“Igniting Innovation”
Why does EMAHSN Engage with Industry?

11. 11
NHS and its relationship with Industry
AHSNs first proposed in “Innovation, Health and Wealth”, the NHS is key to
enabling and sustaining economic growth.
“The NHS contributes significantly to the UK economy in four important ways:
• through the services it provides, a healthy population is more productive,
and more economically active
• by adopting innovation to improve its own productivity, it can deliver more
health benefit for a given public resource
• by accelerating adoption and diffusion of innovation, it supports growth in
the health-related industry, helping to create new jobs
• by exporting innovation, ideas and expertise, in partnership with UK
industry.”

12. 1212
EMAHSN Engaging with Industry
“It works at the limits of science – bringing the highest levels of human
knowledge and skill to save lives and improve health.”
EMAHSN core values in building relationships with industry:
1. Improving patient outcomes and experience will be the basis of all
relationships
2. Collaborations supported by EMAHSN will address our clinical themes and
deliver benefits that can be applied to the whole East Midlands
3. There will be mutual benefits for both industry and the NHS in working in
collaboration
4. There will be equitable contribution to collaborations in time and
resources
5. The process and outcomes of collaborations will be transparent to NHS,
industry and the public

13. 13
East Midlands Academic Health Science Network
“Igniting Innovation”
How does EMAHSN Engage with Industry?

14. 14
EMAHSN operational delivery How will we work?

15. 15
Key stages to engage with Industry
“... build alliances across internal and external networks and actively share
latest best practice and provide for rapid evaluation and adoption...”
“Stepping Stones”

16. 16
Transparency – Industry Advisory Panel
16
Role Potential source(s)
Chair EMAHSN Industry Board Member
Pharmaceutical Industry e.g. Association of British Pharmaceutical Industries
Biotechnology Industry e.g. BioIndustry Association, One Nucleus
Technology Industry e.g. Association of British Healthcare Industries,
Medilink, British In Vitro Diagnostics Association
Investor Community e.g. East Midlands Business Angels, regional funds
Local Economic Development Local Enterprise Partnerships, Chamber of Commerce
National Trade Organisation UK Trade and Investment, Technology Strategy Board,
Department of Business Innovation and Skills
NHS representative NHS R&D Director, or Head of the Clinical Research
Network
NHS training representative Director of Innovation, East Midlands Local Education
and Training Board
HEI Representative Head of Enterprise Office
Patient and Carer representative EMAHSN Public, and Patient Involvement group

17. 171717
Emerging theme – Experimental Medicine
East Midlands strength in drug development and formulation.
• Early EMAHSN engagement highlighted key industrial needs
• Lack of awareness of capabilities in NHS and academia
• ”Igniting Innovation” themed event 4th March 2013
• 56 attendees
• NOCRI, Biomedical Research Units, NHS Biobanks, Industry
• “Increasing Research participation”, “Improving Diverse
Populations needs”

18. 18
Emerging theme – Partnership Working
Transformation of health outcomes and the reduction of
unwarranted variation requires system wide changes to care
pathways.
• EMAHSN membership of the ABPI RIG
• Early engagement with communications strategy
• Clinical needs prioritisation
• “Improving Diverse Populations needs”, “Understanding and
supporting the Translation process”
• NICE TA support

19. 19
Expanding engagement
Adding value, not duplicating effort

20. 20
East Midlands Academic Health Science Network
“Igniting Innovation”
What has industry asked from EMAHSN?

21. 21
Feedback from consultations
Simplify, do not become another layer to penetrate!
“The difficulty is trying to simplify the myriad processes; one advantage you bring
is being a simple “front end” so that Industry see you first”
• Better visibility of the assistance available
• Higher profile for NIHR Networks and the current timelines
• Help to promote UK to international pharma
• Assistance to start research and evaluations in the NHS/NIHR
Managed access to NHS and academia, consistent and predictable

22. How can EMAHSN work best with industry?
Simplify, do not become another layer to penetrate!
• Alignment with research engagement with industry
• Additive activities that support the NIHR
• New Partnership Working models
• Opportunities to ‘cross sell’
• New research questions
• Unmet clinical needs
• Robust evaluations

23. 23
Contact details
Professor Rachel Munton, Interim Managing Director
Rachel.munton-ema@nottshc.nhs.uk 0115 82 31300 I 07825 656341
Margaret Woolley, Head of Programme Office
Margaret.Woolley@nhs.net , 07899 964957
Carl Edwards, Interim Industry Lead
Carl.edwards@nottingham.ac.uk 0115 74 84256
Email: emahsn@nottingham.ac.uk
Website: www.emahsn.ac.uk
Telephone: 0115 82 31298
Twitter: @EM_AHSN